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Abstract
Background: Juglans regia has been found to exhibit significant anticancer activity against various human cancer
cell lines. This study was undertaken to isolate the active chemical constituent (Juglone) and to investigate its
cytotoxic activity along with its various analogs against different human cancer cell lines.
Methods: Isolation of juglone, a napthoquinone, from the chloroform extract of the root part of Juglans regia was
executed by flash chromatography using silica gel as stationary phase. The isolated Juglone was used as starting
material for the further synthesis of a novel series of triazolyl analogs using click chemistry approach to investigate
their cytotoxic potential against different human cancer cell lines using 3-(4,5-Dimethylthiazol-yl)-diphenyl
tetrazoliumbromide (MTT) assay.
Results: The different extracts of Juglans regia and the isolated compound (juglone) exhibited satisfactory cytotoxic
activity against a panel of eight different human cancer cell lines namely, prostate colon (Colo-205 and HCT-116),
breast (T47D), prostate (PC-3 and DU-145), skin (A-431) and lung (NCI-H322 and A549). Interestingly, all the
synthesised analogs displayed enhanced and selective cytotoxic activity against lung cancer cell lines only. Of
the synthesized derivatives, 15a and 16a displayed the best activity with IC50 of 4.72 and 4.67 μM against A549
cells. Both these derivatives exhibited superior potency to BEZ-235 against both the lung cancer cell lines. So far
as the structural aspects are concerned, electron withdrawing substituents at the ortho position of R moiety of the
triazolyl analogs seem to be essential for attaining better activity.
Conclusion: The present study demonstrates the selective and enhanced cytotoxic activity of the triazolyl analogs
of juglone against NCI-H322 and A549 human lung cancer cell lines. Some derivatives exhibited superior potency
to BEZ-235, a commercially available anticancer agent.
Background
Juglans regia Linn. also known as Persian walnut, white
walnut, English walnut or common walnut, belongs to
the family juglandaceae. It is widely distributed in
southern Europe, northern Africa, eastern Asia, the
USA and western South America [1]. China is the leading
world producer of walnut, followed by the USA, Iran,
Turkey, Ukraine, Romania, France and India [2]. Juglans
regia leaves have been used worldwide in traditional
system of medicine as antimicrobial, antihelmintic, astrin-
gent, antidiarrhoeal, hypoglycaemic, depurative, tonic,
carminative, and for the treatment of sinusitis, cold and
stomach ache [3, 4]. In Turkish folk medicine, its leaves
are used to reduce fever and to alleviate the rheumatic
pain [5, 6]. The kernel of J. regia has been used for the
treatment of inflammatory bowel disease in Iranian trad-
itional medicine [7]. The bark, branches and exocarp of
the immature green fruit of this medicinal plant have been
used to treat gastric, liver and lung cancer in China [8, 9].
The herbal preparations of walnut (Juglans) have been
reported in Chinese traditional medicine for the treatment
of a host of diseases including cancer [10, 11].
Quinones have been extensively scrutinised for their
potential anticancer activities and such research
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programmes have yielded numerous clinically significant
scaffolds like doxorubicin, mitoxanthrone, siantropin etc.
However, due to the prevalence of drug resistance many
more anticancer agents are still under scrutiny [12, 13].
Juglone (5-hydroxy-1,4-naphthaquinone) is one such
pharmacologically active napthoquinone isolated from
various Juglans (family: Juglandaceae) species. Previous
studies have demonstrated the potential anticancer activ-
ity of juglone in various in vivo tumour models [14–18].
In addition to this, recent studies have shown the signifi-
cant cytotoxic activity of juglone against various cancer
cell lines [19, 20]. The cytotoxic activity of juglone is pri-
marily attributed to induction of reactive oxygen species
which leads to an altered redox homeostasis in the cell
causing apoptotic as well as necrotic cell death. Addition-
ally, juglone is believed to inhibit Pin1 (Peptidyl-prolyl
isomerase), known to be over-expressed in many cancer
types and has been hypothesized to be a chemotherapeutic
drug target [21–25]. Juglone has also been reported to
exert certain toxic effects to normal tissues causing acute
irritant contact dermatitis [25].
Despite the excellent anticancer potential, quinones
present high lipophilicity. The high lipophilicity facilitates
easy permeation through biomembranes thereby enhan-
cing their cytotoxicity in vitro, but the higher lipophilicity
considerably reduces their bioavailability in vivo. The
cellular delivery of anticancer molecules is an important
aspect in the field of anticancer therapy and several means
have been employed for improving the bioavailability as
well as enhancing the activity and reducing their toxicity.
These limitations of the anticancer chemotherapies could
be overcome by introduction of hydrogen bond donors
like N and O, thereby enhancing the aqueous solubility,
improved pharmacokinetic potential and therefore im-
proved bioavailability. In this connection, the concept of
click chemistry inspired synthesis of triazolyl analogs
seems to be a sensible path, wherein three nitrogen
atoms are incorporated in a five membered heterocyclic
ring.
Click chemistry [26] has recently attracted great atten-
tion from the medicinal chemists primarily in the field
of triazolyl analog synthesis of natural products includ-
ing alkaloids [27, 28], coumarins [29, 30], saponins [31],
steroids [32] and triterpenes [33]. Triazole derivatives
have a great reputation in medicinal chemistry and have
been successfully used as antiviral, antibacterial, antifun-
gal, anti-tuberculosis, anticonvulsant, antidepressant, anti-
inflammatory and anticancer agents [34, 35]. Anastrozole,
letrozole and vorozole are some important examples of
clinically significant triazole derived antineoplastic drugs
[35]. Therefore, the design and synthesis of natural prod-
uct derived triazolyl analogs is the prospective path for the
development of novel antineoplastic agents with better
activity, lower toxicity as well as higher selectivity.
Inspired by above cited literature and the potential
anticancer activity of triazoles in general and juglone in
particular, we designed this work towards the synthesis of
a diverse series of novel triazolyl analogs of biological
interest using juglone (1) as an important starting mater-
ial. All the triazolyl analogs along with different extracts of
Juglans regia were subjected to MTT [3-(4,5-Dimethyl-
thiazol-yl)-diphenyl tetrazoliumbromide] cytotoxicity
assay against a panel of eight different human cancer cell
lines namely, prostate colon (Colo-205 and HCT-116),
breast (T47D), prostate (PC-3 and DU-145), skin (A-431)
and lung (NCI-H322 and A549) to check their cytotoxic
potential. To the best of our knowledge, there are no
reports on the synthesis of triazolyl analogs of juglone
and their bioevaluation. This work provides the initial
report on structure-activity relationship of triazolyl an-
alogs of juglone with the aim to prepare analogs with
enhanced bioavailability, lesser toxicity, better activity
and improved selectivity. This strategy would provide
an important step towards the rationalisation of lead
properties of juglone.
Methods
All the solvents and reagents for the preparation of ex-
tracts, chemical synthesis and biological assays were ob-
tained from Sigma Aldrich. The chemical reactions were
monitored by using F254 silica gel TLC plates (E. Merck)
using ceric ammonium sulphate and UV torch for the
detection of spots. All the compounds were purified by
column chromatography on silica gel (60–120 mesh). 1H
NMR and 13C NMR spectra (with chemical shifts
expressed in δ and coupling constants in Hertz) were re-
corded on Bruker DPX 400 instrument using CDCl3 as
the solvent with TMS as internal standard. High reso-
lution mass spectra (HRMS) were recorded on Agilent
Technologies 6540 instrument and IR recorded on an FT-
IR Bruker (270–30) spectrophotometer. Melting points of
compounds were recorded on Buchi melting point
apparatus.
Plant materials
The bark of Juglans regia was collected from Wenzhou,
China and the dried voucher specimen (No. JR 0014)
was deposited in the herbarium of the Wenzhou Medical
University, China.
Preparation of plant extracts
The air-dried chopped plant material was extracted with
different organic solvents including hexane, chloroform,
ethyl acetate and methanol separately at room temperature
for 24 h (three times). These extracts were then concen-
trated under reduced pressure at 35 °C using a rotary evap-
orator (Buchi, Switzerland).
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Isolation of juglone
Juglone was isolated in good amount from the root parts
of Juglans regia (duly authenticated by the taxonomist).
Juglone was isolated through repeated column chroma-
tography over silica gel 60–120 mesh from the chloroform
extract and characterized by spectral data analysis and by
comparing with the authentic sample.
Synthesis of 2 (Scheme 1)
To a solution of juglone (1) (2 g, 11.49 mmol) in aceto-
nitrile (10 ml), NaH (530 mg, 22.98 mmol) was added
portionwise and stirred for 10 min at 20 °C. Propargyl
bromide (1.5 ml, 15 mmol) was then added drop wise and
the suspension was stirred for 2 h. Progress of reaction
was monitored using TLC at regular intervals. After the
completion of reaction, the reaction mixture was extracted
with ethyl acetate (3x30 ml) which on subsequent purifi-
cation over silica gel column resulted in the isolation of
pure product 2 in 67 % yield. Colourless solid, mp: 125 °C.
1H NMR (CDCl3, 400 MHz) δ: 7.78 (m, 2H), 7.28 (d, J =
8.1 Hz, 1H), 6.95 (m, 2H), 4.43 (s, 2H), 2.50 (s, 1H). 13C
NMR (126 MHz, CDCl3) δ: 190.53, 184.50, 161.70, 139.84,
138.89, 136.80, 132.01, 124.74, 119.40, 115.22, 79.20,
76.54, 58.80. HR-ESIMS m/z: calculated for C13H8O3 [M
+H]+ 213.0553, found 213.0595.
General procedure for synthesis of azides
The azides were prepared as per the known method [29].
To a solution of particular aromatic amine in 1,4-Dioxane
(at the rate of 50 mg/ml) at −15.0 °C, 5 equivalents of 2 M
Sulphuric acid was added in small instalments while
stirring. After 5 min 2 equivalents of 3 M sodium nitrite
was added drop wise and after 30 min 3 equivalents of
3 M sodium azide was added drop wise carefully. Reaction
was brought to room temperature and extracted with di-
ethyl ether for at least three times. Organic layers were
washed with saturated sodium bicarbonate solution two
times, dried over anhydrous sodium sulphate and concen-
trated to a minimum volume under reduced pressure on
rotavapour.
General procedure for synthesis triazolyl derivatives
(15a to 20a)
Compound 2 (3 mmol) and different freshly prepared or-
ganic azides (3 mmol) were sonicated in 10 ml of a 2:1
water:t-butanol mixture with sodium ascorbate (0.3 mmol,
300 μL of freshly prepared 1 M solution in water) followed
by copper (II) sulfate pentahydrate (0.03 mmol, in 100 μl
of water). The reaction mixture was extracted with ethyl
acetate (30x3 ml) and the combined organic layer was
dried over sodium sulphate and purified through column
Scheme 1 Reagents and conditions: (a) Propargyl bromide, NaH, acetonitrile, rt, 3 h (b) N3R, CuSO4.5H2O, sodium ascorbate, t-butanol:H2O (1:1),
rt, 30 min
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chromatography to give pure products in excellent yields
of 85–90 %.
5-((1-(2-Nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy)juglone 15a
Yellow liquid; Yield: 87 %; 1H NMR (400 MHz, CDCl3)
δ: 1H NMR (CDCl3, 400 MHz) δ: 8.07 (d, J = 8.0 Hz,
1H), 7.96 (s, 1H), 7.80 (t, J = 8.0 Hz, 1H), 7.75 (m, 2H),
7.69 (m, 2H), 7.25 (d, J = 8.0 Hz, 1H), 6.92 (2H, m), 4.40
(s, 2H). 13C NMR (126 MHz, CDCl3) δ: 191.02, 185.10,
160.77, 146.47, 144.41, 139.84, 138.89, 136.80, 133.80,
132.01, 130.63, 130.37, 127.62, 125.45, 124.74, 124.21,
119.40, 115.22, 65.25. HR-ESIMS m/z: calculated for
C19H12N4O5 [M +H]
+ 377.0816, found 377.0859.
5-((1-(3-Nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy)juglone 15b
Yellowish liquid; Yield: 88 %; 1H NMR (400 MHz,
CDCl3) δ: 8.60 (s, 1H), 8.30 (m, 1H), 8.26 (s, 1H), 8.18
(m, 1H), 7.75 (m, 3H), 7.30 (d, J = 8.0 Hz, 1H), 6.98 (m,
2H), 4.24 (s, 2H). 13C NMR (126 MHz, CDCl3) δ:
190.88, 185.21, 161.72, 148.99, 140.11, 138.92, 137.86,
136.97, 132.33, 131.01, 125.84, 124.74, 123.08, 120.59,
120.59, 120.11, 115.62, 115.01, 65.44. HR-ESIMS m/z:




Yellow liquid; Yield: 88 %; 1H NMR (400 MHz, CDCl3) δ:
8.44 (d, J = 9.0 Hz, 2H), 8.29 (s, 1H), 7.98 (d, J = 9.0 Hz,
2H), 7.81 (m, 2H), 7.29 (d, J = 8.0 Hz, 1H), 6.97 (2H, m),
4.29 (s, 2H). 13C NMR (126 MHz, CDCl3) δ: 190.60,
184.34, 161.65, 147.61, 147.12, 141.24, 139.91, 138.88,
136.80, 132.05, 125.58, 125.58, 124.04, 120.56, 120.30,
120.30, 119.41, 115.02, 59.81. HR-ESIMS m/z: calculated
for C19H12N4O5 [M+H]
+ 377.0816, found 377.0861.
5-((1-(2-Cyanophenyl)-1H-1,2,3-triazol-4-yl)methoxy)juglone
16a
Yellowish liquid; Yield: 89 %; 1H NMR (400 MHz,
CDCl3) δ: 8.35 (s, 1H), 7.86 (m, 3H), 7.80 (m, 2H), 7.63
(m, 1H), 7.30 (d, J = 8.0 Hz, 1H), 6.97 (2H, m), 4.23 (s,
2H). 13C NMR (126 MHz, CDCl3) δ: 190.62, 184.44,
161.68, 146.69, 140.10, 138.92, 138.68, 136.82, 134.39,
134.39, 132.06, 129.46, 124.66, 125.37, 123.15, 119.49,
115.70, 115.20, 65.12. HR-ESIMS m/z: calculated for
C20H12N4O3 [M +H]
+ 357.0917, found 357.1002.
5-((1-(3-Cyanophenyl)-1H-1,2,3-triazol-4-yl)methoxy)juglone
16b
Yellow liquid; Yield: 85 %; 1H NMR (400 MHz, CDCl3)
δ: 8.35 (m, 1H), 8.25 (s, 1H), 8.16 (m, 1H), 7.80 (m, 2H),
7.65 (m, 1H), 7.68 (t, J = 8.2 Hz, 1H), 7.29 (d, J = 8.0 Hz,
1H), 6.92 (m, 2H), 4.25 (s, 2H). 13C NMR (126 MHz,
CDCl3) δ: 190.65, 184.64, 162.04, 147.10, 146.61, 141.20,
139.92, 138.87, 136.57, 132.00, 125.51, 125.51, 124.77,
120.55, 120.25, 119.99, 114.82, 120.25, 65.31. HR-ESIMS





Yellow liquid; Yield: 95 %; 1H NMR (400 MHz, CDCl3) δ:
8.20 (s, 1H), 7.92 (d, J = 8.8 Hz, 2H), 7.86 (d, J = 8.8 Hz,
2H), 7.82 (m, 2H), 7.34 (d, J = 8.0 Hz, 1H), 6.99 (m, 2H),
4.23 (s, 2H). 13C NMR (126 MHz, CDCl3) δ: 191.09,
185.21, 161.88, 147.48, 140.47, 139.95, 133.95, 138.99,
136.97, 133.95, 131.88, 124.52, 120.43, 120.43, 120.40,
120.02, 117.71, 115.77, 65.36. HR-ESIMS m/z: calculated
for C20H12N4O3 [M+H]
+ 357.0917, found 357.1003.
5-((1-(2-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)juglone
17a
Yellow liquid; Yield: 89 %; 1H NMR (400 MHz, CDCl3)
δ: 8.2 (s, 1H), 7.80 (m, 2H), 7.77 (d, J = 8.0 Hz, 1H), 7.42
(m, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.10 (m, 2H), 6.93 (m,
2H), 4.22 (s, 2H), 3.60 (s, 3H). 13C NMR (126 MHz,
CDCl3) δ: 191.08, 184.82, 162.34, 151.10, 139.98, 138.73,
136.49, 131.71, 130.05, 126.33, 125.68, 125.52, 125.42,
121.35, 121.21, 119.88, 115.38, 112.18, 65.32, 55.60. HR-





Yellow liquid; Yield: 90 %; 1H NMR (400 MHz, CDCl3)
δ: 8.10 (s, 1H), 7.74 (m, 2H), 7.38 (m, 2H), 7.25 (m, 1H),
7.22 (d, J = 8.0 Hz, 1H), 6.93 (m, 2H), 6.97 (m, 1H), 4.23
(s, 2H), 3.62 (s, 3H). 13C NMR (126 MHz, CDCl3) δ:
189.92, 183.80, 161.34, 145.96, 139.25, 137.91, 137.12,
136.22, 132.05, 130.49, 124.44, 120.91, 119.76, 119.04,
115.18, 114.49, 112.29, 106.21, 65.41, 55.62. HR-ESIMS





Yellow liquid; Yield: 88 %; 1H NMR (400 MHz, CDCl3) δ:
8.05 (s, 1H), 7.79 (m, 2H), 7.66 (d, J = 8.8 Hz, 2H), 7.28 (d,
J = 8.0 Hz, 1H), 7.05 (d, J = 8.8 Hz, 2H), 6.97 (m, 2H), 4.59
(s, 2H), 3.88 (s, 3H). 13C NMR (126 MHz, CDCl3) δ:
190.75, 184.88, 161.37, 159.77, 146.19, 139.83, 138.19,
136.77, 132.14, 130.53, 124.91, 122.21, 122.21, 121.18,
119.53, 115.31, 114.74, 114.74, 65.42, 55.62. HR-ESIMS
m/z: calculated for C20H15N3O4 [M+H]
+ 362.1071, found
362.1131.
Zhang et al. BMC Complementary and Alternative Medicine  (2015) 15:396 Page 4 of 8
5-((1-(2-Bromophenyl)-1H-1,2,3-triazol-4-yl)methoxy)juglone
18a
Yellowish liquid; Yield: 88 %; 1H NMR (400 MHz, CDCl3)
δ: 8.07 (s, 1H), 7.77 (m, 3H), 7.56 (m, 1H), 7.49 (m, 1H),
7.39 (m, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.03 (m, 2H), 4.25
(s, 2H). 13C NMR (126 MHz, CDCl3) δ: 190.88, 184.72,
161.70, 145.28, 140.20, 138.92, 136.83, 136.71, 133.94,
132.19, 131.07, 128.48, 128.20, 124.73, 124.74, 119.40,
118.48, 115.22, 65.35. HR-ESIMS m/z: calculated for
C19H12BrN3O3 [M+H]




Yellow liquid; Yield: 88 %; 1H NMR (400 MHz, CDCl3)
δ: 8.06 (s, 1H), 7.81 (m, 2H), 7.42 (m, 2H), 7.30 (m, 1H),
7.18 (d, J = 8.0 Hz, 1H), 6.95 (m, 2H), 7.01 (m, 1H), 4.30
(s, 2H). 13C NMR (126 MHz, CDCl3) δ: 190.12, 183.38,
161.52, 145.10, 138.71, 137.08, 137.15, 136.25, 132.12,
130.55, 125.02, 120.18, 119.55, 118.82, 115.51, 114.76,
112.30, 106.15, 65.77. HR-ESIMS m/z: calculated for
C19H12BrN3O3 [M +H]




Yellow liquid; Yield: 89 %; 1H NMR (400 MHz, CDCl3)
δ: 8.09 (s, 1H), 7.82 (m, 2H), 7.67 (d, J = 9.1 Hz, 2H),
7.63 (d, J = 9.1 Hz, 2H), 7.31 (d, J = 8.0 Hz, 1H), 6.92 (m,
2H), 4.23 (s, 2H). 13C NMR (126 MHz, CDCl3) δ:
190.89, 184.65, 161.70, 146.15, 139.92, 138.98, 137.15,
135.12, 132.02, 131.91, 131.91, 124.25, 121.28, 120.80,
120.80, 119.59, 119.53, 115.22, 64.40. HR-ESIMS m/z:
calculated for C19H12BrN3O3 [M+H]
+ 410.0070, [M+ 2]+
411.0042, found 410.0180, 411.0140.
5-((1-Phenyl-1H-1,2,3-triazol-4-yl)methoxy)juglone 19a
Yellow liquid; Yield: 90 %; 1H NMR (400 MHz, CDCl3)
δ: 8.10 (s, 1H), 7.76 (m, 4H), 7.54 (m, 2H), 7.44 (m, 1H),
7.29 (d, J = 8.0 Hz, 1H), 6.99 (m, 2H), 4.24 (s, 2H). 13C
NMR (126 MHz, CDCl3) δ: 190.90, 184.45, 161.79,
146.50, 139.98, 138.92, 137.19, 136.86, 132.35, 129.75,
129.75, 128.68, 124.74, 120.83, 120.48, 120.48, 119.40,
115.27, 65.55. HR-ESIMS m/z: calculated for C19H13N3O3
[M+H]+ 332.0965, found 332.1018.
5-((2-Chlorophenyl-1H-1,2,3-triazol-4-yl)methoxy)juglone
20a
Yellow liquid; Yield: 89 %; 1H NMR (400 MHz, CDCl3)
δ: 8.10 (s, 1H), 7.76 (m, 3H), 7.42 (m, 1H), 7.35 (d, J =
8.0 Hz, 1H), 7.12 (m, 2H), 6.95 (m, 2H), 4.22 (s, 2H). 13C
NMR (126 MHz, CDCl3) δ: 190.98, 185.04, 161.68,
145.48, 140.04, 138.92, 136.90, 134.98, 132.12, 130.79,
130.67, 128.46, 127.94, 127.75, 124.69, 124.38, 119.14,
115.18, 65.32. HR-ESIMS m/z: calculated for
C19H12ClN3O3 [M + H]
+ 366.0575, found 366.0638.
MTT [3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium
bromide] assay
All the compounds were evaluated against a panel of
eight different human cancer cell lines namely prostate
colon (Colo-205 and HCT-116), breast (T47D), prostate
(PC-3 and DU-145), skin (A-431) and lung (NCI-H322
and A549) using MTT assay in a 96 well plate. Cells
were routinely maintained in RPMI 1640 (Sigma Aldrich)
supplemented with 10 % FBS (Merck) and 1 % penicillin
G and streptomycin (Sigma Aldrich) at 37 °C in a humidi-
fied incubator with 5 % CO2 and were subcultured at 1:5
ratio once a week. For antiproliferative activity, com-
pounds were dissolved in cell culture grade DMSO.
Briefly, cells (104 cells/well) were cultured in 96 well tissue
culture plates and treated with different concentrations of
compounds for 48 h. At the end of incubation, 20 μL of
MTT (2.5 mg/mL) was added to the wells and incubated
for 4 h. Absorbance was recorded at 570 nm using Eliza
Plate Reader. Inhibition of formation of coloured MTT
formazan was taken as an index of cytotoxicity activity.
Further the IC50 values on the cancer cells of different
tissue origin used for screening were determined by
non-linear regression analysis using graph pad prism
software [36].
Results
Extraction, isolation and preparation of juglone analogs
In this study, the different extracts of Juglans regia bark
were prepared using hexane, chloroform, ethyl acetate
and methanol separately and subjected to cytotoxic ac-
tivity at 100 μM concentrations. Among these extracts,
chloroform extract displayed the best activity at prelim-
inary cytotoxicity screening against prostate colon
(Colo-205 and HCT-116), breast (T47D), prostate (PC-3
and DU-145), skin (A-431) and lung (NCI-H322 and
A549) cancer cell lines. Chloroform extract was further
chromatographed on a flash chromatograph leading to
the isolation of the active compound i.e. juglone.
Juglone (1) was used as the starting material and was
subjected propargylation at the only hydroxyl group with
propargyl bromide in presence of NaH in acetonitrile to
form 5-prop-2-yn-1-yloxy-juglone (2) (Scheme 1). The
structure of 2 was confirmed by spectral data analysis.
From the elemental analysis and HR-ESIMS (m/z
213.0595), this compound was assigned the molecular for-
mula C13H8O3. Proton singlets in
1H-NMR at δ 2.50 and
4.43 integrating for one and two protons respectively,
were assigned to terminal alkyne proton and two
methylenic protons of propargylic moiety respectively.
The alkylated product (2) was allowed to undergo
Huisgen 1, 3-dipolar cycloaddition reaction with freshly
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prepared aromatic azides under sharpless click chemis-
try conditions [CuSO4.5H2O and sodium ascorbate in
t-BuOH:H2O (1:1)] to yield regioselectively 1,4-disub-
stituted-1,2,3-triazoles (15a to 20a) in excellent yields
(Scheme 1). A diverse series of triazolyl analogs of juglone
was prepared for SAR studies. All the synthesised analogs
were characterised by spectral data analysis. The formation
of products was confirmed by a triazole proton singlet at
around 8.0 ppm in its 1H-NMR spectrum besides the other
aromatic signals. 13C NMR and HR-ESIMS techniques
were also employed for the characterisation of products.
Anti-proliferative activity
All the newly synthesized analogs along with the juglone
and different extracts were screened through MTT cyto-
toxicity assay against a panel of eight human cancer cell
lines including prostate colon (Colo-205 and HCT-116),
breast (T47D), prostate (PC-3 and DU-145) and skin (A-
431) and lung (NCI-H322 and A549). The parent juglone
(1) and chloroform extract exhibited broad-spectrum
cytotoxicity against all the tested cancer cells. Interest-
ingly, at the preliminary screening concentration (50 μM),
all the triazolyl anaolgs displayed selective cytotoxicity
against lung (NCI-H322 and A549) cancer cell lines in a
dose dependent manner. The other cell lines were inef-
fectively sensitized at the preliminary screening. In order
to generate the IC50 values, all the derivatives were further
assayed at different concentrations (2–50 μM) against
NCI-H322 and A549 cell lines (Table 1). The IC50 values
are the average of triplicate analysis. In this assay the anti-
cancer BEZ-235 was used as a positive control.
Among the synthesized analogs, 15a and 16a bearing
an o-nitro and o-cyanophenyl R moieties respectively,
displayed the best activity against both the lung cancer
cell lines. 16a exhibited the IC50 of 4.67 and 7.94 μM
against A549 and NCI-H322 cells respectively, while as,
15a displayed the IC50 of 4.72 and 8.90 μM against
A549 and NCI-H322 cells respectively. Both these de-
rivatives displayed better cytotoxic activity than the
standard BEZ-235 against A549 and NCI-H322 cells.
17a, 17b and17c with o, m and p-methoxyphenyl R
moieties respectively were weakly active towards both
the tested cancer cell lines. Among these derivatives,
17b with m-methoxyphenyl R moiety displayed slightly
better activity than the corresponding o and p-methox-
yphenyl counterparts. The analogs 18a, 18b and 18c
bearing o, m and p-bromophenyl R moieties were also
less active than the parent juglone. Herein, the analog
with m-bromophenyl R moiety displayed slightly better
activity than the corresponding derivatives with o and
p-bromophenyl R moieties. Additionally, 19a and 20a
bearing a simple phenyl and o-chlorophenyl R moieties
displayed slightly better activity than juglone but were less
active than the standard BEZ-235. These observations
highlight the role of a particular moiety or a substituent in
attaining the better and selective activity.
Discussion
There is a large collection of synthetic as well as natural
product derived drugs available for the treatment of vari-
ous ailments, but the treatment is often unsatisfactory
because of their severe side effects and drug resistance.
This forms the basis for the synthesis of newer and safer
drugs. The biological importance of quinones is reflected
from the drugs derived from them which include doxo-
rubicin, siantopin etc. Based on the documented anticancer
activity of quinones in general and juglone in particular, we
designed the synthesis of it analogs for improved and se-
lective cytotoxic activity. Juglone is known to exhibit a
broad spectrum cytotoxic activity against various cancer
cell lines. In addition to this, it highly lipophilic and has
therefore limited permeability across biomembranes which
may lower its bioavailability upon oral administration. In
order to overcome these properties, it becomes necessary
to incorporate certain hydrogen bond donors in the form
of heterocyclic ring systems to improve its solubility and
bioavailability for better drug-likeness.
In view of the interesting anticancer activity of
juglone, click chemistry inspired approach (Huisgen 3
+ 2 cycloaddition) involving union of terminal alkynes
with organic azides has been taken up for the synthesis
of regiospecific novel OH linked triazolyl derivatives of
juglone in excellent yields. The target compounds (15a
Table 1 IC50 values of analogs against NCI-H322, A549 cancer lines
Entry Lung (NCI-H322) Lung (A549)
IC50 (μM)
Juglone 19.32 ± 0.83 16.70 ± 0.88
15a 8.90 ± 0.20 4.72 ± 0.20
15b 15.60 ± 0.83 12.86 ± 0.48
15c 10.96 ± 0.68 10.20 ± 0.43
16a 7.94 ± 0.34 4.67 ± 0.18
16b 17.22 ± 1.18 15.08 ± 0.92
16c 13.30 ± 0.87 12.95 ± 0.81
17a 29.08 ± 1.20 23.83 ± 1.54
17b 26.52 ± 1.20 20.28 ± 1.15
17c 32.88 ± 1.63 25.32 ± 1.77
18a 24.34 ± 1.28 20.55 ± 0.82
18b 21.82 ± 1.25 19.12 ± 0.89
18c 24.55 ± 1.54 20.26 ± 0.72
19a 18.98 ± 0.99 15.12 ± 0.47
20a 18.28 ± 0.96 12.88 ± 0.42
BEZ-235 9.80 ± 0.25 6.28 ± 0.28
BEZ-235 was used as positive control
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to 20a) were synthesized as in appreciable yields as
highlighted in Scheme 1.
16a bearing o-cyanophenyl R moiety exhibited the
IC50 of 4.67 and 7.94 μM against A549 and NCI-H322
cells respectively, while as, 15a with o-nitrophenyl R
moiety exhibited the IC50 of 4.72 and 8.90 μM against
A549 and NCI-H322 cells respectively. In addition to
this, 17a, 17b and 17c with o, m and p-methoxyphenyl
R moieties respectively were weakly active towards the
tested cancer cell lines. 18a, 18b and 18c bearing o, m
and p-bromophenyl R moieties also exhibited less activ-
ity than juglone.
The results of this work signify that the compounds
carrying an electron withdrawing groups (–NO2 and –
CN) in the R moieties displayed better cytotoxicity than
juglone, while as, the analogs with electron donating
functionalities (–OMe and –Br) in the R moieties were
weakly cytotoxic against both the lung cancer cell lines.
Additionally, analogs with simple phenyl and o-chloro-
phenyl R moieties had little effect on the activity of the
parent molecule (juglone). The results of this work re-
veal the effect of a particular substituent and its position
on the cytotoxic activity profile of juglone. However, in
vivo studies on 15a and 16a, the most active analogs,
are warranted to investigate the exact mechanisms of
action responsible for their cytotoxicity.
Conclusions
The current study is the first report involving the syn-
thesis of triazolyl analogs of juglone and the evaluation
their in vitro cytotoxic activity using MTT assay. In this
study, we have demonstrated the cytotoxic activity of a
diverse library of novel triazolyl analogs of juglone pre-
pared through Cu(I) catalyzed click chemistry approach
(Huisgen 3 + 2 cycloaddition) and characterized by the
analysis spectral and analytical data. Among the synthe-
sized analogs, 15a and 16a were identified as highly active
and selective cytotoxic agents against NCI-H322 and
A549 human cancer cell lines. Both these derivatives ex-
hibited better biological activity than BEZ-235 against
both the lung cancer cell lines. So far as the SAR is con-
cerned, electron withdrawing substituents at the ortho
position of R moiety of triazoles seem to be essential for
attaining the better activity.
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